ALBION TECHNOLOGY & GENERAL VCT PLC

Financial Health Assessment: ALBION TECHNOLOGY & GENERAL VCT PLC

1. Financial Health Score: B+

Explanation: The patient exhibits excellent structural and regulatory health, with a robust governance framework and a flawless compliance record. However, the grade is held back slightly from an 'A' due to the absence of key portfolio performance metrics (the "blood work") in this specific diagnostic snapshot. As a Venture Capital Trust (VCT), the true financial wellness lies in the performance of its underlying investments, which requires a deeper dive into the full annual report.

2. Key Vital Signs

• Pulse (Corporate Status & Age): Active & Mature. Incorporated in late 2000, this company has a 24-year operating history. In the high-mortality world of venture capital, surviving over two decades is the equivalent of a remarkably strong resting heart rate.
• Blood Pressure (Filing Compliance): Optimal. There are no signs of regulatory stress. Accounts are filed up to date (last made up to 31 Dec 2025) with the next due date comfortably in the future, and the confirmation statement is also current. No overdue filings mean the company is breathing easily without the constriction of regulatory penalties.
• Immune System (Corporate Governance): Very Strong. The board features a diverse and experienced lineup of 12 directors, including a designated independent director and a corporate secretary (Albion Capital Group LLP). This large, multi-disciplinary board acts as a powerful immune system against mismanagement, ensuring oversight and strategic direction are well-maintained.
• DNA (Business Nature): SIC Code 64303. This identifies the company as a Venture and Development Capital company. It is important to note that the £4.00 share capital is entirely normal for a VCT; the nominal share capital is merely the legal shell. The actual financial "muscle" is held within the investment portfolio and reserves, which are not detailed in this dataset.

3. Diagnosis

Structurally Robust, Awaiting Portfolio Blood Work

From a corporate and regulatory perspective, Albion Technology & General VCT PLC is the picture of health. The patient is not in any form of financial distress, insolvency, or administrative shock. The transition from its previous name (Close Technology & General VCT PLC) in 2009 appears to have been a successful "transplant" or rebranding procedure, with the entity thriving under the Albion banner since then.

However, a complete diagnosis of an investment trust requires examining the net asset value (NAV), dividend history, and the health of the underlying investee companies. Because this particular snapshot only provides the corporate shell data, we can confirm the shell is exceptionally well-maintained, but we cannot measure the growth or yield of the underlying portfolio assets.

4. Recommendations

To maintain and confirm its excellent health, the following "preventative care" and monitoring steps are recommended:

1. Order Full Blood Work (Review the Full Annual Report): Stakeholders should obtain the full financial statements to check the Net Asset Value (NAV) per share, total return, and dividend yield. This will confirm whether the investment portfolio is generating healthy returns or showing symptoms of stagnation.
2. Continue Regulatory Wellness Checks: Maintain the current pristine track record of on-time filings with Companies House to avoid unnecessary regulatory fevers or penalties.
3. Monitor Board Vitality: With a board of 12, ensure that director tenures are reviewed periodically to prevent board fatigue and maintain fresh strategic perspectives.